These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24974488)

  • 1. Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
    Panda C
    J Assoc Physicians India; 2013 Nov; 61(11):785-8. PubMed ID: 24974488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
    Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
    Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    Piratvisuth T; Komolmit P; Tanwandee T; Sukeepaisarnjaroen W; Chan HL; Pessôa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Cheinquer H; Pathan R; Dong Y; Trylesinski A
    PLoS One; 2013; 8(2):e54279. PubMed ID: 23390496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
    Murray KF; Szenborn L; Wysocki J; Rossi S; Corsa AC; Dinh P; McHutchison J; Pang PS; Luminos LM; Pawlowska M; Mizerski J
    Hepatology; 2012 Dec; 56(6):2018-26. PubMed ID: 22544804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
    Sulaiman A; Lesmana LA; Nafrialdi ; Helyanna
    Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.